Logo image of CLDI

CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Fundamental Analysis

NYSEARCA:CLDI - NYSE Arca - US3207033099 - Common Stock - Currency: USD

1.05  -0.21 (-16.67%)

After market: 1.0899 +0.04 (+3.8%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to CLDI. CLDI was compared to 571 industry peers in the Biotechnology industry. CLDI has a bad profitability rating. Also its financial health evaluation is rather negative. CLDI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLDI has reported negative net income.
CLDI had a negative operating cash flow in the past year.
CLDI Yearly Net Income VS EBIT VS OCF VS FCFCLDI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of CLDI (-387.44%) is worse than 96.98% of its industry peers.
Industry RankSector Rank
ROA -387.44%
ROE N/A
ROIC N/A
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLDI Yearly ROA, ROE, ROICCLDI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 2K 4K 6K 8K 10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLDI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDI Yearly Profit, Operating, Gross MarginsCLDI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

CLDI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLDI has been increased compared to 1 year ago.
CLDI has a better debt/assets ratio than last year.
CLDI Yearly Shares OutstandingCLDI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M
CLDI Yearly Total Debt VS Total AssetsCLDI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

CLDI has an Altman-Z score of -40.73. This is a bad value and indicates that CLDI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -40.73, CLDI is doing worse than 93.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -40.73
ROIC/WACCN/A
WACC8.62%
CLDI Yearly LT Debt VS Equity VS FCFCLDI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 -10M -20M -30M -40M

2.3 Liquidity

A Current Ratio of 0.12 indicates that CLDI may have some problems paying its short term obligations.
CLDI has a worse Current ratio (0.12) than 98.05% of its industry peers.
CLDI has a Quick Ratio of 0.12. This is a bad value and indicates that CLDI is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.12, CLDI is doing worse than 98.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
CLDI Yearly Current Assets VS Current LiabilitesCLDI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.45% over the past year.
Looking at the last year, CLDI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)2.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.24%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 25.21% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.59%
EPS Next 2Y39.45%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLDI Yearly Revenue VS EstimatesCLDI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
CLDI Yearly EPS VS EstimatesCLDI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLDI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLDI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDI Price Earnings VS Forward Price EarningsCLDI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDI Per share dataCLDI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

CLDI's earnings are expected to grow with 25.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.45%
EPS Next 3Y25.21%

More info and screens

0

5. Dividend

5.1 Amount

CLDI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CALIDI BIOTHERAPEUTICS INC

NYSEARCA:CLDI (2/21/2025, 8:09:57 PM)

After market: 1.0899 +0.04 (+3.8%)

1.05

-0.21 (-16.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-14 2025-03-14/amc
Inst Owners3.46%
Inst Owner Change271.37%
Ins Owners11.66%
Ins Owner Change2.46%
Market Cap27.22M
Analysts87.5
Price Target6.38 (507.62%)
Short Float %2.7%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.36%
Min EPS beat(2)4.02%
Max EPS beat(2)28.7%
EPS beat(4)3
Avg EPS beat(4)-19.39%
Min EPS beat(4)-129.55%
Max EPS beat(4)28.7%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)6.88%
EPS NY rev (3m)6.88%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.6
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS-0.45
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -387.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-531.04%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z -40.73
F-Score1
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)148.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.24%
EPS Next Y73.59%
EPS Next 2Y39.45%
EPS Next 3Y25.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-102.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.2%
OCF growth 3YN/A
OCF growth 5YN/A